Among patients with heart failure with preserved ejection fraction (HFpEF), lower versus higher ranges of EF signal fundamentally different morphologies and hemodynamic responses, which may have ...

The combined benefits of a mineralocorticoid receptor antagonist (MRA), an angiotensin receptor-neprilysin inhibitor (ARNI), and a sodium-glucose cotransporter 2 (SGLT2) inhibitor in patients with ...

WILMINGTON, Del.--(BUSINESS WIRE)--Today, new results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of FARXIGA ® ...

Dapagliflozin significantly reduced the risk of cardiovascular (CV) death or worsening of heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFpEF), according to ...

Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Finerenone improved outcomes in patients with heart ...

Tackling rhythm control early, with ablation or antiarrhythmic medication in the first year after atrial fibrillation (Afib) diagnosis, helped outcomes in people with heart failure (HF), a ...

Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...

BOSTON -- Early cardiac resynchronization therapy (CRT) benefited patients with moderately reduced ejection fraction (EF) and left bundle branch block (LBBB) but no indication for pacing, according to ...

Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...